Gemcitabine monophosphate is a novel HDAC inhibitor with broad-spectrum antitumor activity against solid (IC50: 30 to 300 nM) and hematological malignancies. Gemcitabine monophosphate was found to be a potent inhibitor of HDAC1 and -8 (class I) in vitro.